Suvica is a biotechnology company structured around discovery and development of small molecules for cancer treatment. Currently, they have a small molecule protein synthesis inhibitor (SVC112 ) in pre-clinical development for a variety of cancer indications, including head & neck cancer, melanoma, colorectal cancer, and non-small cell lung cancer. With a patent filed for Composition of Matter protection, SVC112 has shown pre-clinical efficacy as monotherapy and in combination with standard therapies such as radiation and newly approved targeted agents. SuviCa Inc. and the University of Colorado have an exclusive license agreement for a CU drug screening technology to identify novel therapies for cancer developed by CU-Boulder Associate Professor Tin Tin Su - CSO and Co-founder of the firm. The underpinning work involves a genetically modified Drosophila fruit fly model to screen for compounds effective against various types of cancer, either alone or in combination with existing therapies. The screening technique will be used to identify new clinical candidates using a methodology that is both time efficient and cost-effective. Because it uses a whole-animal screening model, the technique can more easily eliminate drug candidates with undesired toxicity.